Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.35 |
| ▸ | GLS | O94925 | 2/20 | 0.34 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126163 | 0.88 | PDK1 (0.36) | SMN1; SMN2PDK1BRD4 | |
| SCHEMBL4130961 | 0.84 | HTR2C (0.37) | HTR2CSLC6A4F2GLSGBA1 | |
| SCHEMBL4118500 | 0.82 | HTR2C (0.36) | HTR2CSLC6A4F2GLSGBA1 | |
| SCHEMBL3650554 | 0.81 | HTR2C (0.37) | HTR2CSLC6A4F2GLSGBA1 | |
| SCHEMBL3652834 | 0.79 | HTR2C (0.34) | HTR2CSLC6A4F2GLSGBA1 | |
| SCHEMBL3693347 | 0.78 | BRD4 (0.36) | HTR2CAGTR2BRD4 | |
| SCHEMBL3654644 | 0.78 | HTR2C (0.38) | HTR2CSLC6A4F2GLSGBA1 | |
| Hydrochloric Acid SCHEMBL3645132 | 0.77 | GLS (0.34) | HTR2CSLC6A4F2GLSPDK2 | |
| Hydrochloric Acid SCHEMBL4132294 | 0.77 | BRD4 (0.37) | BRD4 | |
| SCHEMBL3654948 | 0.76 | F2 (0.35) | HTR2CSLC6A4F2GLSAGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | HTR2C 2565/4885SLC6A4 3372/4885F2 2233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.